Earnings ·
Repligen Corporation reported second quarter 2026 financial results and updated its full-year guidance
RGENRepligen Corp
Repligen Corporation reported second quarter 2026 financial results and updated its full-year guidance. Q2 revenue reached $204 million, a 12% year-over-year increase, while GAAP operating income remained flat at $14 million. Adjusted operating income rose 55% to $34 million, and adjusted diluted EPS was $0.54. The company raised its full-year 2026 organic revenue growth guidance to 10.5%-13.5% and adjusted EPS guidance to $2.03-$2.09. Repligen also announced a definitive agreement to acquire BioLife Solutions to strengthen its cell therapy capabilities. The company operates in the life sciences industry, developing and commercializing bioprocessing technologies and systems for biological drug manufacturing.